CEFSULODIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H20N4O8S2
Molecular Weight	532.546
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SCC(C[N+]3=CC=C(C=C3)C(N)=O)=C(N1C(=O)[C@H]2NC(=O)[C@@H](C4=CC=CC=C4)S(O)(=O)=O)C([O-])=O

InChI

InChIKey=SYLKGLMBLAAGSC-QLVMHMETSA-N

InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C22H20N4O8S2
Molecular Weight	532.546
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/3536385 | http://www.229877.com/article/2013/0126/32350.html

Cefsulodin is a third-generation of cephalosporin antibiotic with a narrow spectrum of activity. It has a specific activity against Pseudomonas aeruginosa. Cefsulodin’s targets are bacterial penicillin binding proteins. Drug is indicated for the treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. Cefsulodin appears to be well tolerated and relatively free of any significant toxicity except for nausea and vomiting.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 233 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2112536 \| https://www.ncbi.nlm.nih.gov/pubmed/3545069 \| https://www.ncbi.nlm.nih.gov/pubmed/3898066	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Lower respiratory tract infections 51 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8429	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Urinary tract infections 205 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8429	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Skin and soft tissue infections 33 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8429	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Gynecological infections 8 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8429	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Bone and joint infections 27 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8429	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Intra-abdominal infections 49 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8429	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
CNS infections 2 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8429	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Sepsis 71 Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo	Curative	Approved 8429	Takesulin Approved Use Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.

PubMed

Title	Date	PubMed
Epitope analysis of aztreonam by antiaztreonam monoclonal antibodies and possible consequences in beta-lactams hypersensitivity.	1992	1384868

Patents

Sample Use Guides

In Vivo Use Guide

Intramuscular: 0.5-1 g daily in 2-4 divided doses Intravenous: 0.5-1 g. in severe cases up to 2 g.

Route of Administration: Other

In Vitro Use Guide

Cefsulodin was an effective bactericidal agent against P. aeruguiosa and S. aureus. An apparent decrease in the number of living bacteria was observed at a concentration of 6.25 ug/ml for P. aerugnosa U 31 and 3.13 ug/ml for S. aureus FDA 209- P.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:36:30 UTC 2023` Edited by `admin` on `Fri Dec 15 15:36:30 UTC 2023`
Record UNII	OV42LHE42B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CEFSULODIN

Official Name

English

CEFSULODIN [MI]

Common Name

English

cefsulodin [INN]

Common Name

English

4-CARBAMOYL-1-(((6R,7R)-2-CARBOXY-8-OXO-7-((2R)-2-PHENYL-2-SULFOACETAMIDO)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYLPYRIDINIUM HYDROXIDE, INNER SALT

Common Name

English

CEFSULODIN [JAN]

Common Name

English

Cefsulodin [WHO-DD]

Common Name

English

J01DD03

Code

English

Classification Tree Code System Code

WHO-ATC

J01DD03